

This week in therapeutics

| Indication | Target/marker/ pathway | Summary | Licensing status | Publication and contact information |
|---------------------|--|--|---|--|
| Inflammation | | | | |
| Allergy | Sphingosine-1-phosphate receptor 1 (S1PR1; S1P1; EDG1); protease-activated receptor 2 (PAR2) | <p>Studies in mice suggest that agonizing S1PR1 or PAR2 could help prevent vascular leak in allergy-associated inflammatory diseases. In a mouse model of allergy-induced vascular leak, S1pr1 knockout animals had higher levels of leak and edema and lower survival than wild-type controls. S1pr1-deficient and wild-type mice treated with agonists of S1PR1 or PAR2 had lower induced vascular leak than mock-treated controls. Next steps could include testing the effects of S1PR1 agonists in mouse models of allergy-induced vascular leak. Fingolimod (FTY720), an S1PR1 agonist from Novartis AG, is in Phase III testing to treat relapsing-remitting multiple sclerosis (RRMS). R3477, an S1PR1 agonist from Actelion Ltd. and Roche, is in Phase I testing to treat MS.</p> <p>SciBX 2(26); doi:10.1038/scibx.2009.1053 Published online July 9, 2009</p> | Patent and licensing status unavailable | <p>Camerer, E. <i>et al. J. Clin. Invest.</i>; published online June 15, 2009; doi:10.1172/JCI38575</p> <p>Contact: Shaun R. Coughlin, University of California, San Francisco, Calif. e-mail: shaun.coughlin@ucsf.edu</p> |